124 related articles for article (PubMed ID: 38205940)
1. Genetic variants in the mTOR pathway with renal cancer risk and subtypes in East Indian population.
Malakar S; Chatterjee S; Das M; Pal DK
Urologia; 2024 May; 91(2):270-275. PubMed ID: 38205940
[TBL] [Abstract][Full Text] [Related]
2. A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk.
Cao Q; Ju X; Li P; Meng X; Shao P; Cai H; Wang M; Zhang Z; Qin C; Yin C
PLoS One; 2012; 7(11):e50302. PubMed ID: 23209702
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
4. Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines.
Bodnar L; Stec R; Cierniak S; Synowiec A; Wcisło G; Jesiotr M; Koktysz R; Kozłowski W; Szczylik C
Ann Oncol; 2015 Jul; 26(7):1385-9. PubMed ID: 25962440
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of gypenosides of Gynostemma pentaphyllum inducing apoptosis of renal cell carcinoma by PI3K/AKT/mTOR pathway.
Liu H; Li X; Duan Y; Xie JB; Piao XL
J Ethnopharmacol; 2021 May; 271():113907. PubMed ID: 33556477
[TBL] [Abstract][Full Text] [Related]
7. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
8. Candidate tumor suppressor and pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma.
Zeng L; Bai M; Mittal AK; El-Jouni W; Zhou J; Cohen DM; Zhou MI; Cohen HT
Cancer Res; 2013 Sep; 73(17):5371-80. PubMed ID: 23824745
[TBL] [Abstract][Full Text] [Related]
9. MiR-182 affects renal cancer cell proliferation, apoptosis, and invasion by regulating PI3K/AKT/mTOR signaling pathway.
Fu JH; Yang S; Nan CJ; Zhou CC; Lu DQ; Li S; Mu HQ
Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):351-357. PubMed ID: 29424922
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel mycocompounds as inhibitors of PI3K/AKT/mTOR pathway against RCC.
Yadav RP; Chatterjee S; Chatterjee A; Pal DK; Ghosh S; Acharya K; Das M
J Recept Signal Transduct Res; 2022 Dec; 42(6):599-607. PubMed ID: 36125981
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA regulates development of diabetes retinopathy through the PI3K/Akt/mTOR pathway.
Guan R; Kang Z; Li L; Yan X; Gao T
PLoS One; 2024; 19(1):e0295813. PubMed ID: 38194422
[TBL] [Abstract][Full Text] [Related]
12. Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling.
Yang Z; Xie H; He D; Li L
Oncotarget; 2016 Jul; 7(28):44478-44491. PubMed ID: 27283897
[TBL] [Abstract][Full Text] [Related]
13. [Total polyphenols of Cydonia oblonga inhibited proliferation and migration of renal cancer cells by PI3K/Akt/mTOR pathway].
Abudurousuli K; Han MY; Hailati S; Maihemuti N; Talihati Z; Nueraihemaiti N; Dilimulati D; Baishan A; Aikebaier A; Zhou WT
Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):1052-1063. PubMed ID: 38621912
[TBL] [Abstract][Full Text] [Related]
14. Energy balance, polymorphisms in the mTOR pathway, and renal cell carcinoma risk.
Shu X; Lin J; Wood CG; Tannir NM; Wu X
J Natl Cancer Inst; 2013 Mar; 105(6):424-32. PubMed ID: 23378641
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of apoptosis through AKT-mTOR pathway in ovarian cancer and renal cancer.
Chen H; Zhang L; Zuo M; Lou X; Liu B; Fu T
Aging (Albany NY); 2023 Feb; 15(4):1210-1227. PubMed ID: 36849137
[TBL] [Abstract][Full Text] [Related]
16. Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models.
Qian CN; Furge KA; Knol J; Huang D; Chen J; Dykema KJ; Kort EJ; Massie A; Khoo SK; Vanden Beldt K; Resau JH; Anema J; Kahnoski RJ; Morreau H; Camparo P; Comperat E; Sibony M; Denoux Y; Molinie V; Vieillefond A; Eng C; Williams BO; Teh BT
Cancer Res; 2009 Nov; 69(21):8256-64. PubMed ID: 19843858
[TBL] [Abstract][Full Text] [Related]
17. Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma.
Campbell L; Jasani B; Edwards K; Gumbleton M; Griffiths DF
Br J Cancer; 2008 Mar; 98(5):931-40. PubMed ID: 18283322
[TBL] [Abstract][Full Text] [Related]
18. miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.
Huang J; Wang X; Wen G; Ren Y
Oncol Rep; 2019 Nov; 42(5):1677-1688. PubMed ID: 31545453
[TBL] [Abstract][Full Text] [Related]
19. Integrated analysis identifies microRNA-188-5p as a suppressor of AKT/mTOR pathway in renal cancer.
Shen H; Jin J; Wang H; Yu N; Liu T; Sheng H; Wan Z; Feng C; Huang Y; Gao F
Cancer Sci; 2023 Aug; 114(8):3128-3143. PubMed ID: 37199297
[TBL] [Abstract][Full Text] [Related]
20. The prospect of precision therapy for renal cell carcinoma.
Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F
Cancer Treat Rev; 2016 Sep; 49():37-44. PubMed ID: 27453294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
